Alto Neuroscience, Inc. Stock Analysis & AI Score
Alto Neuroscience, Inc. (ANRO) has an ST Score of 49.8 (C+), driven by its Profitability (B+) and held back by its Growth (F). Analysts rate it Buy with a $38.00 price target (+39.8% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NYSE |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Alto Neuroscience, Inc. (ANRO) has an ST Score of 49.8 (C+), driven by its Profitability (B+) and held back by its Growth (F). Analysts rate it Buy with a $38.00 price target (+39.8% upside).
- Strongest
- ProfitabilityB+
- Weakest
- GrowthF
All factor grades
- ProfitabilityB+
- Financial StrengthB+
- MomentumB
- ForecastB
- ValuationB-
- GrowthF
- Piotroski2/9
Contact
ANRO stock: frequently asked questions
What is ANRO's ST Score?
Alto Neuroscience, Inc. (ANRO) has an ST Score of 49.8 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ANRO a buy, hold, or sell?
Analysts rate ANRO a Buy, with a price target of $38.00 (+39.8% vs the current price). Our ST Score grades it C+ (49.8/100). The ST Score is a data-driven signal, not a recommendation.
What are ANRO's factor grades?
Valuation B-, Profitability B+, Financial Strength B+, Momentum B, Growth F, Forecast B.
What is ANRO's valuation grade?
Alto Neuroscience, Inc. (ANRO) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ANRO's growth grade?
Alto Neuroscience, Inc. (ANRO) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ANRO's profitability grade?
Alto Neuroscience, Inc. (ANRO) earns a profitability grade of B+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ANRO's financial strength grade?
Alto Neuroscience, Inc. (ANRO) earns a financial strength grade of B+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ANRO?
The average analyst price target for Alto Neuroscience, Inc. (ANRO) is $38.00 from 9 analysts, which is +39.8% versus the recent price of $27.18.
What is ANRO's Piotroski score?
Alto Neuroscience, Inc. (ANRO) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.